Login to Your Account



Washington Roundup


Tuesday, December 18, 2012
The Federal Trade Commission (FTC) approved a final order settling charges that Parsippany, N.J.-based Watson Pharmaceuticals Inc.'s proposed acquisition of Actavis Inc., of Zug, Switzerland, would have been anticompetitive in the markets for 21 current and future generic drugs used to treat a range of conditions from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription